Skip to content

Iovance Biotherapeutics, Inc. IOVA Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Immunome logo
ImmunomeIMNM
$2.83M-32.1%
Nuvation Bio logo
Nuvation BioNUVB
$3.6M-32.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$2.26M+7.8%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$7.39M-17.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.98B+32.4%
Enterprise value$1.83B+33.2%
P/S6.9×-0.1×

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s operating lease ROU assets?
Iovance Biotherapeutics, Inc. (IOVA) reported operating lease ROU assets of $44.38M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s operating lease ROU assets changed year-over-year?
Iovance Biotherapeutics, Inc.'s operating lease ROU assets decreased by 12.8% year-over-year, from $50.9M to $44.38M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease ROU assets?
Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s operating lease ROU assets has grown at a -3.5% compound annual growth rate (CAGR), from $54.76M to $45.9M.
What does operating lease ROU assets mean?
This asset represents the company's right to use a leased item, such as office space or data center facilities, over the lease term. It is recognized under modern accounting standards to reflect the financial commitment of long-term operating leases. It provides visibility into the company's fixed operational footprint.